Abstract
Emerging evidence indicates that the apolipoprotein E (APOE) ε4 exacerbates α-synuclein pathology. To determine whether APOE ε4 contributes to motor progression in early Parkinson's disease (PD). Longitudinal data were obtained from 384 patients with PD divided into APOE ε4 carriers (n=85) and noncarriers (n=299) in the Parkinson's Progression Marker Initiative. Participants underwent yearly motor assessments over a mean follow-up period of 78.9 months. Repeated measures and linear mixed models were used to test the effects of APOE ε4. The motor progression was significantly more rapid in patients with PD carrying APOE ε4 than in noncarriers (β=0.283, P=0.026, 95% confidence interval: 0.033-0.532). Through subgroup analysis, we found that the effect of APOE ε4 was significant only in patients with high amyloid β burden (β=0.761, P < 0.001, 95% confidence interval: 0.0356-1.167). APOE ε4 may be associated with rapid motor progression in PD. © 2021 International Parkinson and Movement Disorder Society.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
